- Home
- SPRO vs GGR Comparison
SPRO vs GGR Comparison
Compare SPRO & GGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPRO
- GGR
- Stock Information
- Founded
- SPRO 2013
- GGR 2011
- Country
- SPRO United States
- GGR Taiwan
- Employees
- SPRO N/A
- GGR N/A
- Industry
- SPRO Biotechnology: Pharmaceutical Preparations
- GGR Auto Manufacturing
- Sector
- SPRO Health Care
- GGR Consumer Discretionary
- Exchange
- SPRO Nasdaq
- GGR Nasdaq
- Market Cap
- SPRO 121.0M
- GGR 101.1M
- IPO Year
- SPRO 2017
- GGR N/A
- Fundamental
- Price
- SPRO $1.90
- GGR $0.33
- Analyst Decision
- SPRO Buy
- GGR Hold
- Analyst Count
- SPRO 4
- GGR 2
- Target Price
- SPRO $5.00
- GGR $0.50
- AVG Volume (30 Days)
- SPRO 323.5K
- GGR 259.4K
- Earning Date
- SPRO 11-13-2025
- GGR 11-13-2025
- Dividend Yield
- SPRO N/A
- GGR N/A
- EPS Growth
- SPRO N/A
- GGR N/A
- EPS
- SPRO N/A
- GGR N/A
- Revenue
- SPRO $48,576,000.00
- GGR $289,420,000.00
- Revenue This Year
- SPRO N/A
- GGR N/A
- Revenue Next Year
- SPRO N/A
- GGR $5.00
- P/E Ratio
- SPRO N/A
- GGR N/A
- Revenue Growth
- SPRO N/A
- GGR N/A
- 52 Week Low
- SPRO $0.51
- GGR $0.19
- 52 Week High
- SPRO $3.22
- GGR $0.89
- Technical
- Relative Strength Index (RSI)
- SPRO 40.19
- GGR 41.45
- Support Level
- SPRO $1.91
- GGR $0.32
- Resistance Level
- SPRO $2.18
- GGR $0.33
- Average True Range (ATR)
- SPRO 0.09
- GGR 0.02
- MACD
- SPRO 0.00
- GGR -0.00
- Stochastic Oscillator
- SPRO 11.94
- GGR 22.03
About SPRO Spero Therapeutics Inc.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
About GGR Gogoro Inc.
Gogoro Inc is focused on eliminating the barriers to electric fuel adoption to bring swappable electric power within reach of every urban rider. Its battery swapping technology compromises an interoperable platform that seamlessly integrates a comprehensive ecosystem of hardware, software, and services, which consists of Gogoro Smart Batteries, GoStations, Gogoro Network Software & Battery Management Systems, Smartscooter, and related components and kits. Geographical presence in Taiwan and Other countries, majority of its revenue comes from Tiwan.